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Abstract 
After decades of intense research on genetic alterations in cancer and successful implementation of 
genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully 
recognized. The discovery of frequent mutations in genes modifying the epigenome in diffuse large 
B-cell lymphoma (DLBCL) has highlighted the outstanding role of epigenetic deregulation in this 
disease. Identification of epigenetically-driven DLBCL subgroups and development of novel 
epigenetic drugs have rapidly advanced. However, further insights are needed into the biological 
consequences of epigenetic alterations and the possibility of restoring the aberrant epigenome with 
specific therapies to bring this treatment concept further into clinical practice. This review will 
summarize the main epigenetic changes found in DLBCL and their potential for precision medicine 
approaches. 
 
Highlights 
 The most frequent epigenetic alterations in DLBCL are described  
 We review potential targets for epigenetic therapies in DLBCL 
 The current clinical development of epigenetic drugs and future direction for combination 
therapies are outlined  
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Background 
Approximately one third of patients with diffuse large B-cell lymphoma (DLBCL) relapse after first-
line therapy. Outcome of relapsed/refractory DLBCL remains poor and there is an unmet need for 
novel agents to improve treatment of this patient population. Remarkable progress has recently 
been made in the development of “epigenetic drugs” and in our understanding of the epigenetic 
basis of DLBCL. Epigenetics define mechanisms of regulating cellular functions without changing the 
genetic code. Key elements of the epigenome are chromatin modifications in form of DNA 
methylation as well as post-translational modifications of histones. This review will focus on 
chromatin modifications and their potential as therapeutic targets in DLBCL. 
Chromatin is built of nucleosomes, a complex of DNA wrapped around an octamer of histone 
proteins, two of each histone H2A, H2B, H3 and H4 (Figure 1). Histone residues can be modified by 
methylation and acetylation, but also ubiquination, phosphorylation and sumoylation. These histone 
“marks” are predominantly found at arginine and lysine residues of histone tails. Similarly, DNA can 
be marked by methylation of cytosines that are part of CG dinucleotides (CpGs). Epigenetic marks 
modify the conformational structure of chromatin and thereby access and recruitment of proteins 
essential for key cellular functions such as transcription, DNA repair and replication.1  
Several enzymes, so called epigenetic modifiers, are involved in concerting the epigenetic code, 
which are broadly categorized into “writers”, “erasers” and “readers”. Writers add epigenetic marks 
to the chromatin e.g. acetylate or methylate histone residues or CpGs [histone acetyltransferases 
(HATs), histone methyltransferases (HMTs), DNA methyltransferases (DNMTs)]. Accordingly, eraser 
proteins catalyze removal of these marks and comprise histone deacetylases (HDACs), histone 
demethylases (HDMTs) and DNA demethylases. Readers are effector proteins that recognize and 
bind epigenetic marks through specific domains (e.g. bromo- and chromo-domains) and induce 
downstream molecular changes such as activation/repression of gene expression or recruitment of 
DNA repair proteins. 
The effect of epigenetic marks on gene transcription is complex and context-dependent.1 DNA 
methylation in gene promoters is often associated with gene silencing, whereas gene body 
methylation is frequently linked to transcriptional activation. Histone methylation (mono-, di- and 
tri-methylation) is frequently found at histone H3, lysine residues 4, 9, 27, 36 and 79.2 Methylation 
of H3 at lysine 4 (H3K4me) represents a histone mark associated with activation of gene expression. 
In contrast, H3K27me typically results in gene silencing.2 Of note, promoter or enhancer regions 
controlling transcriptional activity can also be in a bivalent (poised) state, when both repressive and 
activating marks are present. Given the magnitude of epigenetic marks that co-occur at a specific 
genomic region, the functional implications of individual marks have to be interpreted in a broader 
context.1 
Epigenetic modifications are key regulatory elements for normal cell development, controlling 
important cellular growth and survival pathways. Epigenetic patterns undergo substantial changes 
during cell differentiation, but also dynamic changes in response to various external stimuli.1 This 
allows for a rapid on/off-switch of selected genes to adapt cells to particular requirements, such as 
changes during transition from naïve B-cell to plasma cell maturation. 
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Epigenetic changes in DLBCL 
The significant role of epigenetics in the development of DLBCL and other germinal center (GC) 
lymphomas like follicular lymphoma (FL) was highlighted by the high incidence of somatic mutations 
in epigenetic modifiers discovered by next-generation sequencing studies. Genes most frequently 
affected encode for the HMTs EZH2 and KMT2D, as well as the HATs CREBBP and EP300.3–6 Nearly all 
of these mutations are heterozygous. Allele frequencies in lymphoma cell subsets indicate that they 
are driver lesions occurring early during lymphomagenesis.7,8 Mutations in epigenetic modifiers lead 
to aberrant patterns of epigenetic marks and thus perturbation of cellular activities. The shared 
biological consequence of the above mentioned mutations is transcriptional repression of specific 
target genes: through gain-of-function of transcriptional repressors like EZH2, or loss-of-function of 
transcriptional activators like KMT2D or CREBBP/EP300. Similar downstream effects can also be 
induced by mutations of transcription factors regulating epigenetic modifiers or by genes affecting 
metabolites that influence activity of these enzymes.  
Perturbation of DNA methylation has also been implicated in the pathogenesis of DLBCL. In this 
regard, focal hypermethylation can lead to silencing of tumor suppressor genes, and global 
hypomethylation is believed to contribute to lymphomagenesis through genomic instability. 
Interestingly, recent studies have demonstrated that a number of transcription factors bind 
preferentially to hypermethylated DNA, demonstrating regulatory function of DNA methylation 
beyond established concepts.9 In contrast to myeloid malignancies, DNA methylation changes in 
DLBCL are not linked to mutations of DNMTs and underlying mechanisms have yet to be defined. 
On the basis of alterations in epigenetic modifiers and patterns of epigenetic marks, epigenetically 
driven subgroups of DLBCL are now increasingly being recognized and will help to identify suitable 
candidates for epigenetic therapy approaches.  
Targeting the DLBCL epigenome 
Histone lysine methylation 
KMT2D 
Mutations of KMT2D (also known as MLL2) are found in 20-35% of DLBCL, both in germinal center B-
cell (GCB) and activated B-cell (ABC) subtypes.4–6 Notably, the incidence of KMT2D mutations 
exceeds 80% in patients with FL.4,10 The HMT KMT2D is a subunit of a protein complex that activates 
transcription through methylation of H3K4, predominantly at enhancer regions.11 Mutations are 
widely distributed over the entire KMT2D gene and are mostly truncating and missense mutations 
leading to loss of its enzymatic function.5 The majority of DLBCL cases harbor heterozygous 
mutations without evidence of inactivation of the second allele, suggesting KMT2D to be a 
haploinsufficient tumor suppressor.5,12 First data on the functional role of KMT2D in lymphoma 
development have only recently been published, confirming tumor suppressor properties of the 
protein associated with loss of H3K4 methylation.12,13 Target genes of KMT2D include regulators of 
immune signalling, toll-like receptor- and B-cell receptor signalling pathways.13 Knockout of KMT2D 
promoted lymphoma development in FL/DLBCL mouse models.12,13 Interestingly, KMT2D was shown 
to preferentially methylate bivalent promoters in embryonic stem cells, a unique feature among 
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KMT2 family members.14 Thus, disruption of bivalency at poised promoters might play a role in the 
pathogenesis of KMT2D-deficient lymphomas.   
So far, there is no specific treatment for KMT2D mutated DLBCL. One potential approach could be 
the development of inhibitors of histone demethylases that counteract KMT2D function. Another 
interesting area is the design of molecules that modulate reader proteins of KMT2D-induced marks 
to restore the defective KMT2D pathway.15 In addition, there is evidence for cross-talk between 
histone methylation and acetylation networks and HDAC inhibitors were shown to increase 
methylation at H3K4.16 In a study investigating Kabuki syndrome, a rare disorder associated with loss 
of KMT2D, HDAC inhibitor treatment restored the neurodevelopmental phenotype in a Kabuki 
syndrome mouse model.17 It will be interesting to see whether DLBCL cases harboring KMTD2 
mutations show differential response to HDAC inhibitors with H3K4 methylation properties.   
EZH2 
EZH2 is a H3K27 methyltransferase which is mutated in 20-30% of GCB DLBCL and rarely in ABC 
subtypes.3,18 EZH2 is the key enzymatic component of the Polycomb Repressor Complex 2 (PRC2). 
EZH2-mediated mono-, di- and trimethylation of H3K27 leads to silencing of a magnitude of genes,19 
the specific set of target genes being cell-type dependent. In B-cells, EZH2 plays an essential role 
during GC formation. EZH2 is transiently up-regulated in centroblasts promoting cell proliferation by 
suppressing the cell cycle inhibitor CDKN1A and blocking differentiation by silencing IRF4 and 
PRDM1, genes essential for plasma cell maturation.20  
Mutations of EZH2 are predominantly heterozygous gain-of-function mutations affecting the 
catalytic SET domain, mostly at Y641.3 Mutant EZH2 has improved di- and trimethylation efficiency, 
but is defective of H3K27 monomethylation, thus requiring presence of the wild-type enzyme.21 
EZH2-mediated gene silencing through H3K27 trimethylation mainly occurs at promoters that are 
activated by H3K4me3 marks, resulting in their transcriptional poising.20 Presence of EZH2 mutation 
locks cells in the GC state by maintaining repression of GC exit genes, facilitating malignant 
transformation.20 Mutant EZH2 is not sufficient to induce lymphoma development, but was shown to 
accelerate BCL2- and MYC-driven lymphomagenesis.20,22 
Several small inhibitors of EZH2 have been developed. EZH2 inhibitor treatment was shown to 
induce up-regulation of EZH2 targets and bivalent genes and suppressing EZH2-associated 
proliferation in GCB cells.20 In ABC lymphoma cells, EZH2 inhibition leads to de-methylation of 
H3K27, but without significant impact on cellular growth.20 Interestingly, anti-tumor activity was also 
seen in GCB DLBCL without EZH2 mutation20 and consequently clinical trials are enrolling both wild-
type and mutated cases at present. Three compounds are currently tested in phase I/II trials – 
tazemetostat (Epizyme), GSK2816126 (GlaxoSmithKline), and CPI-1205 (Constellation 
Pharmaceuticals). A recent update on a phase II trial of single-agent tazemetostat in 
relapsed/refractory B-cell Non-Hodgkin lymphoma (NHL) showed remarkable efficacy, particularly in 
EZH2 mutated FL with an ORR of 92%.23 Response to tazemetostat in DLBCL seem to also depend on 
the EZH2 mutational status with 5/17 (29%) responders in EZH2 mutant compared to 18/119 (15%) 
in wildtype cases.23 Further data of correlative biomarker studies in DLBCL will reveal how strongly 
activity of EZH2 inhibitors depends on the EZH2 mutational status, cell-of-origin categories or other 
molecular characteristics of DLBCL. 
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Histone acetylation 
CREBBP and EP300 
The two interacting histone acetyltransferases CREBBP and EP300 are mutated in around 30% of 
DLBCL.24 Both proteins are highly homologous and acetylate lysine residues of histones as well as 
non-histone substrates. Mutations are predominantly located in the catalytic HAT domain and lead 
to reduced acetylation activity and potentially dominant-negative effects.24,25 Reduced acetylation 
levels of H3K4 and H3K18 have been shown in DLBCL cell lines after knockdown of wild-type p300 
protein.26 Current data indicate that CREBBP and EP300 are haploinsufficient tumor suppressors, and 
several mechanisms have been described to account for this function, e.g. alteration of BCL6 and 
p53 activity through reduced acetylation of these proteins24,27 or down-regulation of  NfƙB target 
genes.26 Germline mutations of CREBBP/EP300 are found in the autosomal dominant Rubinstein-
Taybi syndrome which is associated with increased risk of lymphoma.28 Interestingly, CREBBP/EP300-
deficiency seems to have a unique role in B-cell malignancies and are rare in solid tumors.29 
One could speculate that CREBBP/EP300 loss-of-function can be counteracted by treatment with 
HDAC inhibitors and there are pre-clinical data supporting this hypothesis.30 However, another study 
indicated that EP300 mutations confer HDAC inhibitor resistance in DLBCL cells.25 No clear 
association of the CREBBP/EP300 mutational status and response to HDAC inhibitors has been 
observed in patients so far,31,32 but larger datasets should be awaited before drawing final 
conclusions.  
HDAC inhibition 
HDACs are involved in regulating a variety of cellular functions implicated in cancer development 
and have therefore been investigated as drug targets for many years.33 HDAC inhibitors are currently 
the only class of epigenetic compounds that are approved for the treatment of lymphoma, namely 
for relapsed/refractory peripheral T-cell lymphoma. In DLBCL and other B-cell lymphomas, HDAC 
inhibitors seem to have limited single-agent activity, with overall response rates (ORR) of 5-10% for 
vorinostat and belinostat.34,35 Combination of vorinostat with R-CHOP chemotherapy in the SWOG 
S0806 phase I/II trial did not indicate clinical benefit, but a high rate of infectious complications 
associated with vorinostat.36 Results from two phase II trials suggest higher potency of panobinostat 
in DLBCL with an ORR of 20-29%, including durable responses.32,37 Interestingly, presence of MEF2B 
mutations was associated with response to panobinostat in univariate analysis.32 MEF2B recruits 
HDACs and HATs to target genes and is mutated in 12-15% of DLBCL.4,32,38 Data from independent 
cohorts are needed to confirm whether MEF2B can serve as a biomarker of response to treatment 
with panobinostat or other HDAC inhibitors. 
A major issue of current HDAC inhibitors is lack of specificity: they inhibit several different HDAC 
isotypes, but also modulate acetylation of a wide range of other proteins, such as growth factor 
receptor- and signalling proteins, transcription factors, and DNA repair proteins.39 Accordingly, HDAC 
inhibitors have pleiotropic anti-cancer effects and it is entirely unclear whether histone acetylation 
or non-epigenetic off-target effects account for their anti-tumor activity. It will be essential to 
identify biomarkers of response to HDAC inhibitor treatment, but this is a challenging task with the 
mechanism of action being largely unknown. Development of selective isotype-specific HDAC 
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inhibitors might improve the therapeutic value of these agents.40 In addition, exploiting synergies of 
HDAC inhibition with other cancer pathway inhibitors, like PI3K/mTOR inhibitors41,42 or proteasome 
inhibitors43 will be an important step to take this epigenetic therapy further in the treatment of 
DLBCL.   
BET bromodomain inhibition 
Bromodomains (BRDs) are found in reader proteins of histone lysine acetylation marks such as the 
bromodomain and extraterminal (BET) family of BRD proteins. The BET protein family comprises 
BRD2, BRD3, BRD4, and BRDT. They mediate recruitment of transcription factors and other proteins 
involved in gene transcription.44 No genetic alteration affecting BET proteins is known in lymphoma 
or other hematological malignancies yet. However, critical oncogenes like c-MYC are regulated by 
BET proteins, making them attractive targets for specific therapies.45 Several selective BET 
bromodomain inhibitors have been developed. Phase I data of the first-in-class small molecule BRD2, 
BRD3, and BRD4 inhibitor OTX015 (MK-8628) demonstrated promising efficacy in DLBCL and phase II 
studies are now underway.46 In addition, synergistic effects between BET bromodomain inhibitors 
and other novel agents like HDAC inhibitors,47 ATR inhibitors48 or Bruton’s tyrosine kinase inhibitors49 
warrant further clinical investigation.  
DNA Methylation 
Perturbation of DNA methylation is a hallmark of solid and hematologic malignancies including 
DLBCL.50 The general assumption is that changes in de novo methylation in DLBCL are induced by 
genetic alterations. However, methylation changes could also be initiating events conferring a stem-
like state in lymphoma precursors.51 A high degree of aberrant methylation as well as high intra-
tumor methylation heterogeneity were shown to be associated with poor outcome in DLBCL52–54 and 
might contribute to clonal evolution and acquisition of chemoresistance. When comparing 
presentation and relapse samples of selected DLBCL cases, Pan et al. identified differentially 
methylated promoter and enhancer regions, further supporting a role of DNA methylation in disease 
evolution.54 Intra-tumor methylation heterogeneity was reduced in relapse samples indicative of 
clonal selection. Differential methylation has also been described between ABC and GCB subtypes 
and may contribute to biological differences between these groups.55 In addition to global 
methylation changes in DLBCL, focal hypermethylation of tumor suppressor genes such as KLF4 or 
p16(INK4a) has been reported in several studies.56,57 Despite these interesting novel data, the role of 
DNA methylation in DLBCL development and progression remains largely unclear.  
DNA methylation is mediated by DNA methyltransferases DNMT1, DNMT3A, and DNMT3B, the two 
latter forms being mainly responsible for de novo methylation. Although DNMTs are frequently 
mutated in myeloid malignancies and peripheral T-cell lymphoma, such mutations are rare in B-cell 
lymphomas. Inhibition of DNMTs by cytosine analogs 5-azacytidine or decitabine is supposed to 
restore expression of epigenetically silenced genes. However, our understanding of how these drugs 
impact DNA methylation at specific loci is very limited. Both agents are successfully used in the 
treatment of acute myeloid leukemia and myelodysplastic syndrome, but have limited single-agent 
activity in lymphomas. However, the correct dosing and timing schedules of 5-azacytidine and 
decitabine seem to be crucial. Low-dose application of decitabine was demonstrated to prime DLBCL 
cells for subsequent chemotherapy and counteract mechanisms of resistance.58 A phase I study 
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investigating 5-azacytidine priming before R-CHOP therapy in high risk DLBCL is currently ongoing. In 
addition, combination of DNMT and HDAC inhibitors revealed synergy in in vitro and xenograft 
models59 and should be further explored. With an optimal dose, sequence and combination, 
hypomethylating agents might well play a role in future treatment approaches in DLBCL.   
Conclusion and future directions 
Next-generation sequencing studies have identified mutations of epigenetic modifiers as a hallmark 
event in DLBCL. In particular the discovery of recurrent, activating mutations of EZH2 and insights 
into their biological function opened up avenues of stratified epigenetic therapies. Several early 
phase clinical trials with EZH2 inhibitors are expected to report soon and will hopefully encourage 
further exploration of epigenetic drugs in DLBCL. Besides EZH2, a plethora of other epigenetic 
alterations has been identified in DLBCL, but their role in disease biology and potential as 
therapeutic target remain elusive. Future research on the epigenetic structure of DLBCL and other 
lymphomas will further elucidate the functional consequences of epigenetic alterations and their 
unique role in specific biological subgroups. This will assist in the development of novel epigenetic 
therapies and in defining suitable patient groups for these agents.  
However, with the exception of EZH2 inhibitors, identification of robust biomarkers for epigenetic 
therapies will likely continue to pose a challenge: in contrast to conventional drug targets like 
activated kinases, epigenetic changes are abundant, dynamic and complex to measure. In addition, 
epigenetic marks are cross-linked and their molecular functions are highly context-dependent. A 
better understanding of the molecular effects of epigenetic therapies, including non-epigenetic off-
target effects, and ultimately the development of more specific new generations of epigenetic drugs, 
might facilitate successful biomarker discovery in the future.  
Given the cross-talk of different epigenetic marks in normal and malignant cells, combination of 
epigenetic therapies are anticipated to act synergistically and should be more extensively studied. In 
addition, data on several interesting combinations of epigenetic drugs with various classes of 
targeted and chemotherapeutic agents are eagerly awaited. Finally, the increasing effort of 
integrating large genomic and epigenomic datasets will generate a more comprehensive picture of 
tumor-related alterations and their interaction in order to improve rational combination treatment 
trial design. 
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Figure 1: Epigenetic targets in DLBCL. The schematic figure illustrates DNA wrapped around a 
histone protein complex consisting of histones H2A, H2B, H3 and H4. DNA is methylated (grey) or 
unmethylated (white) at specific CpG sites. Lysine acetylation and methylation marks on histone tails 
can be altered through the presence of somatic mutations in EZH2, KMT2D and CREBBP/EP300, 
respectively. 
 
 
Table 1: Current clinical trials with epigenetic therapies in DLBCL. 
Inhibitor Phase Combination Indication Trial number# 
EZH2 inhibitors 
Tazemetostat 
 
Phase 1/2 Monotherapy Relapsed/refractory DLBCL NCT01897571
23
 
Phase 1/2 R-CHOP First-line DLBCL, high-risk NCT02889523 
GSK2816126 Phase 1 Monotherapy Relapsed/refractory NHL NCT02082977
60
 
CPI-1205 Phase 1 Monotherapy Relapsed/refractory 
lymphoma 
NCT02395601 
HDAC inhibitors 
Romidepsin 
 
Phase 1 Alisertib Relapsed/refractory 
lymphoma 
NCT01897012 
Phase 1/2 Oral azacitidine (CC-486) Relapsed/refractory NHL NCT01998035 
Phase 1* Gemcitabine/dexa-
methasone, cisplatin 
DLBCL and peripheral T-cell 
lymphoma 
NCT01846390 
Vorinostat 
 
Phase 1 Pembrolizumab Relapsed/refractory DLBCL, 
FL, Hodgkin lymphoma 
NCT03150329 
Phase 1/2 Gemcitabine/busulfan/ Relapsed/refractory ABC NCT02589145 
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melphalan, lenalidomide DLBCL 
Phase 2* Bortezomib Relapsed/refractory DLBCL 
and MCL 
NCT00703664 
Phase 1/2* R-CHOP First-line DLBCL NCT00972478
36
 
Belinostat Phase 1 Carfilzomib Relapsed/refractory NHL NCT02142530 
Phase 2* Yttrium Y 90 ibritumomab 
tiuxetan 
Relapsed/refractory NHL NCT01686165 
Panobinostat 
 
Phase 2* Monotherapy Relapsed/refractory NHL NCT01261247 
Phase 1/2* Everolimus Relapsed/refractory 
lymphoma and myeloma 
NCT00918333 
Phase 2* Rituximab Relapsed/refractory DLBCL NCT01238692
32
 
Mocetinostat  Phase 2* Monotherapy Relapsed/refractory DLBCL 
and FL with CREBBP/EP300 
mutation 
NCT02282358 
Hypomethylating agents 
Decitabine  Phase 1/2 R-CHOP First-line DLBCL NCT02951728 
5-azacytidine  Phase 1b  Avelumab/utomilumab Relapsed/refractory DLBCL NCT02951156 
Oral 
azacytidine 
(CC-486) 
Phase 1 R-CHOP First-line DLBCL, high-risk NCT02343536 
Phase 1/2 Romidepsin Relapsed/refractory NHL NCT01998035 
BET inhibitors 
MK-8628 Phase 1b* Monotherapy Relapsed/refractory DLBCL NCT02698189 
INCB057643 Phase 1 Monotherapy Relapsed/refractory NHL NCT02711137 
INCB054329 Phase 1* Monotherapy Relapsed/refractory NHL NCT02431260 
# ClinicalTrials.gov 
* Indicates active study, but not recruiting participants 
 
